Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24430115 | 0.90 | MEN1 (0.44) | MEN1KMT2AKDM4EALDH1A1XDH | |
| SCHEMBL24430113 | 0.89 | MEN1 (0.54) | MEN1KMT2AKDM4EALDH1A1XDH | |
| SCHEMBL24430028 | 0.87 | FAAH (0.46) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL26205783 | 0.86 | MEN1 (0.43) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL24430013 | 0.85 | MEN1 (0.49) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL24430026 | 0.85 | KMT2A (0.52) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL24430024 | 0.84 | MEN1 (0.40) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL24430029 | 0.83 | MEN1 (0.54) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL24437423 | 0.83 | MEN1 (0.50) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL24430114 | 0.83 | MEN1 (0.68) | MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753374-B2 | Compounds for the treatment of acute and chronic kidney disease | Southern Reserach Institute (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753374-B2 | Compounds for the treatment of acute and chronic kidney disease | Southern Reserach Institute (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2022109066-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE | SOUTHERN RESEARCH INSTITUTE (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220153695-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153695-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | HMOX1, GLS, HMOX2 | MEN1 4171/4885KMT2A 2088/4885KDM4E 960/4885 |
| US-11753374-B2 | Compounds for the treatment of acute and chronic kidney disease | HMOX1, GLS, HMOX2 | MEN1 4171/4885KMT2A 2088/4885KDM4E 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.